Biocept

Biocept Cost of Goods Sold

Delisted

The Cost of Goods Sold (COGS) of Biocept (BIOC) as of Nov 3, 2026 is 28.44 M USD. In the previous year, Cost of Goods Sold (COGS) was 37.76 M USD — a change of -24.69% (lower).

Cost of Goods Sold

28.44 MUSD

YoY

-24.69%

Last updated:

Cost of Goods Sold (COGS) of Biocept is 2022 28.44 M USD. Cost of Goods Sold (COGS) of Biocept was 2021 37.76 M USD. It decreases by -24.69% lower compared to the previous year.

The Biocept Cost of Goods Sold history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cost of Goods Sold
Date
Cost of Goods Sold
Jan 1, 2015
4.60 M USD
Jan 1, 2016
6.92 M USD
Jan 1, 2017
9.35 M USD
Jan 1, 2018
10.05 M USD
Jan 1, 2019
10.98 M USD
Jan 1, 2020
21.34 M USD
Jan 1, 2021
37.76 M USD
Jan 1, 2022
28.44 M USD
The Biocept Cost of Goods Sold history
YEARCost of Goods SoldYoY
28.44 MUSD-24.69%
37.76 MUSD+76.99%
21.34 MUSD+94.37%
10.98 MUSD+9.21%
10.05 MUSD+7.56%
9.35 MUSD+35.04%
6.92 MUSD+50.56%
4.60 MUSD+111.75%
2.17 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Biocept Stock analysis

What does Biocept do? Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biocept stock

Cost of Goods Sold (COGS) of Biocept is 28.44 M USD in 2022.

Cost of Goods Sold (COGS) of Biocept changed from 37.76 M USD to 28.44 M USD, representing a -24.69% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cost of Goods Sold (COGS) Biocept since 2006 – with annual values, charts, and detailed analysis.

COGS represents the direct costs attributable to the production of goods sold. It includes material and labor costs directly tied to the product.

Cost of Goods Sold (COGS)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Cost of Goods Sold (COGS)'s Biocept historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Biocept

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Biocept